Global pharmaceutical company committed to eye health
About Our Business
A global pharmaceutical company supporting the eye health of people in more than 60 countries and regions worldwide
We conduct global research and development, manufacturing, sales, and marketing of ophthalmic pharmaceuticals, offering a portfolio of more than 70 products that cover a wide range of eye conditions in over 60 countries and regions.
Number of countries/regions where our products reach patients
More than 60
Overseas business sales ratio*1
44%
Japan*2China*3/Asia*4
No.1
Annual Production Volume5
Approx.
400
Million Units
- *1 Based on FY2024 data.
- *2 Source: Copyright © 2025 IQVIA. JPM 2024.4–2025.3. Santen analysis based on IQVIA data. Reprinted with permission.
- *3 Excluding retina segment. Source: Copyright © 2025 IQVIA. IQVIA MIDAS 2024.Q1–2024.Q4. Santen analysis based on IQVIA data. Reprinted with permission.
- *4 Excluding retina segment. Countries and regions included: South Korea, Vietnam, Thailand, Philippines, Indonesia, Malaysia, Singapore, Taiwan, and Hong Kong. Source: Copyright © 2025 IQVIA. IQVIA MIDAS 2024.Q1–2024.Q4. Santen analysis based on IQVIA data. Reprinted with permission.
- *5 Production at our factory. Single-dose containers are aggregated by counting 10 single-dose containers as 1 bottle. All other products are counted based on the actual number of bottles.
Medium-Term Management Plan
We aim to be a leading ophthalmology company leveraging "Santen Commercial Excellence" to earn the trust of patients and the ophthalmic community worldwide.
We aim to be a leading ophthalmology company leveraging "Santen Commercial Excellence" to earn the trust of patients and the ophthalmic community worldwide.
Santen has formulated a new Medium-Term Management Plan covering fiscal years 2025 to 2029. With a view toward its long-term vision for 2035, the Company aims to transition to a new growth trajectory by executing strategies for sustainable growth while further strengthening its earnings base.
As a global company specialized in eye health, the company pursues steady global growth through highly accurate product development and reliable revenue generation, conducting business activities with a keen focus on providing optimal ophthalmic care based on maximization of product value and innovation born from a deep understanding of both the field of ophthalmology and patient needs.
Research & Development
A Unique Safety and Quality Assurance System that Ensures the Efficacy, Safety, and Quality of Pharmaceuticals at a Global Level
Developing Products and Services Leveraging Our High Ophthalmic Expertise, While Expanding into New Therapeutic Areas such as Myopia and Ptosis
Santen’s R&D is characterized by advanced expertise focused exclusively on ophthalmology. In addition to developing innovative products in existing therapeutic areas, we are pursuing new fields such as myopia and ptosis.
Through collaboration with external partners, we aim to create innovative products and services.
Production and Quality Assurance
A Unique Safety and Quality Assurance System that Ensures the Efficacy, Safety, and Quality of Pharmaceuticals at a Global Level
A Unique Safety and Quality Assurance System that Ensures the Efficacy, Safety, and Quality of Pharmaceuticals at a Global Level
Quality control at Santen is not limited to production, but covers the entire product life cycle, from research and development to marketing to the patient.
We are also actively involved in improving patient quality of life (QOL) and after-sales care, and aim to continue to enhance the reliability of our products and our company.
Under its safety and quality assurance system, Santen has established departments for Quality Assurance (QA), Quality Control (QC), and Safety Vigilance; these departments actively share quality-related information and work together to strengthen safety and quality assurance.
Santen pursues innovation through partnerships and investments with pharmaceutical companies, biotechnology ventures, and academic institutions.
